New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
Patients receiving eptinezumab were four times more likely to achieve a reduction of ≥75% in MMDs within the first 4 weeks, compared to placebo1
The SUNRISE trial met all key secondary efficacy endpoints with improvements seen as early as day 1 and sustained through week 121
VALBY, Denmark, June 21, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced the full results from the SUNRISE trial, a randomized, placebo-controlled trial designed to evaluate the efficacy and safety of eptinezumab versus placebo in a predominantly Asian population with chronic migraine. The study was presented at the 11th Congress of the European Academy of Neurology taking place in Helsinki 21-24 June.1
"Various treatments are recommended for patients with migraine in Asia, however utilization and adherence to migraine-specific treatment is relatively low. Access to effective treatments remains a significant unmet medical need for migraine prevention in Asia" said Johan Luthman, EVP and Head of R&D at Lundbeck. "The data from SUNRISE is consistent with previous results across diverse populations and will be pivotal for our efforts to expand access to eptinezumab for patients in Asia suffering with severe migraine."
The double-blind, pivotal, SUNRISE trial (n=983) met all key primary and secondary endpoints, with eptinezumab demonstrating greater reductions in migraine frequency, the proportion of migraine attacks with severe pain, and disease burden, compared to placebo.1
"The SUNRISE trial marks a significant step forward in the mission to make migraine-specific preventive treatments more globally accessible, ensuring that patients with severe migraine receive the care they need" said Dr Patricia Pozo-Rosich, Head of Section of the Neurology Department, Director of Headache and Craniofacial Pain Clinical Unit and the Migraine Adaptive Brain Center at the Vall d'Hebron University Hospital in Barcelona, and principal investigator in the SUNRISE trial.
In the SUNRISE trial, patients receiving eptinezumab experienced significantly fewer monthly migraine days (MMDs), with eptinezumab offering a -7.5 (300 mg) and -7.2 (100 mg) reduction in MMDs from week 1 through to 12, versus -4.8 with placebo (baseline MMD = 17, p<0.0001 for both 300 mg and 100 mg vs placebo).1
Amongst other parameters, patients receiving eptinezumab (300 mg or 100 mg) were four times more likely to achieve a reduction of ≥75% in the number of migraine days per month, compared to placebo within the first 4 weeks (p<0.0001).1
In the same study, eptinezumab also demonstrated a rapid onset of preventive efficacy, where more participants reported being free of migraine as early as day 1 after receiving eptinezumab treatment compared to placebo (p<0.002 for 300 mg dose; p<0.01 for 100 mg dose). This clinical efficacy was also reflected in patient reported outcomes where patients reported clinically meaningful improvements which were greater with eptinezumab than with placebo.1
Finally, the safety profile of eptinezumab was generally similar to placebo, previous trials, and to the current labelled safety information in the United States prescribing information and EU Summary of Product Characteristics, with the most common treatment-emergent adverse events being COVID-19 and nasopharyngitis.1
Based on the SUNRISE results, Lundbeck has initiated discussions with relevant regulatory authorities with the aim of making eptinezumab available for people suffering from migraine across Asia.
About migraine
Migraine is a complex and incapacitating neurological disease characterized by recurrent episodes of severe headaches typically accompanied by an array of symptoms, including nausea, vomiting, and sensitivity to light or sound. Not only is headache painful, but migraine also imposes both a social and financial burden. Migraine has a profound impact on patient functioning including relationships with family/friends, leisure activities, household production and worker productivity.
Migraine is one of the most prevalent neurological diseases for which medical treatment is sought, and worldwide, is considered the leading cause of disability for people under the age of 50 and the 2nd leading cause of disability worldwide.3,4 Repeated headache attacks, and often the constant fear of the next one, damage family life, social life and work life.
Furthermore, frequent use of acute migraine treatments may leave patients experiencing, or at risk of developing, medication overuse headache. Despite equally high prevalence of migraine in Asia as compared western countries, significant unmet needs remain in terms of sufficient and appropriate diagnosis, and better management and therapies for treatment of migraine in East Asia.5 In China, an estimated 14.3% of adults are living with migraine. From this population, approximately 52.9% will visit hospitals and only 13.8% of them will be diagnosed with migraine.6
About the SUNRISE trial
SUNRISE (NCT04921384) is an interventional, multi-regional, multi-site, randomized, double-blind, placebo-controlled phase III trial, to confirm the efficacy and safety of eptinezumab in participants with chronic migraine who are eligible for preventive treatment.2 The study was conducted to support marketing authorization across Asia.
Chronic migraine was defined as migraine occurring on ≥8 days per month and headache occurring on >14 days. Participants were randomly allocated to one of three treatment groups: eptinezumab 300 mg, eptinezumab 100 mg, or placebo.
The double-blind, placebo-controlled treatment period was followed by an extension period where all participants received active treatment to further assess the safety and tolerability of eptinezumab. The total trial duration from the Screening Visit to the Safety Follow-up Visit is approximately 36 weeks and includes a Screening Period (28-30 days), a Placebo-controlled Period (12 weeks), an Extension Period (12 weeks), and a Safety Follow-up Period (8 weeks).1
Participants in Japan completing the SUNRISE trial were offered to continue in the SUNSET trial (NCT05064371) which consisted of an open-label eptinezumab treatment of 60 weeks (five infusions), and a Safety Follow-up Period (8 weeks).
The SUNRISE was initiated in May 2021 and was conducted in Mainland China, Georgia, Japan, Poland, Slovakia, South Korea, Spain and Taiwan. In the trial, 983 participants were randomized to receive eptinezumab 100 mg or 300 mg or placebo by intravenous (IV) infusion.2
About Vyepti® (eptinezumab)
Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) which was intentionally designed for IV administration. The efficacy and safety of eptinezumab was evaluated in two phase III clinical trials (PROMISE-1 in episodic migraine7 and PROMISE-2 in chronic migraine8), where eptinezumab met its primary endpoint of decrease in MMDs over weeks 1-12 in both episodic and chronic migraine. Furthermore, the clinical trial program demonstrated a treatment benefit over placebo that was observed for both doses of eptinezumab as early as day 1 post-infusion.
The safety of eptinezumab was evaluated in more than 2,000 adult patients with migraine who received at least one dose of eptinezumab. The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity. In PROMISE-1 and PROMISE-2, 1.9% of patients treated with eptinezumab discontinued treatment due to adverse reactions.
Vyepti® (eptinezumab-jjmr) was approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults in February 2020, and in January 2022, eptinezumab was granted marketing authorization by the European Commission (EC) for the prophylaxis of migraine in adults who have at least four migraine days per month. Today, eptinezumab is launched in more than 30 markets worldwide.
Contacts
Marie Petterson
Jens Høyer
Head of Media Relations, Corp. Communication
Vice President, Head of Investor Relations
MEEP@lundbeck.com
JSHR@lundbeck.com
+45 29 82 21 82
+45 30 83 45 01Palle Holm OlesenVice President, Investor RelationsPALO@lundbeck.com+45 30 83 24 26
About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.
Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.
We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.
Lundbeck has approximately 5,700 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.
References:
Yu S, ePresentation at EAN Congress 2025
H. Lundbeck A/S. Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine (Sunrise). Clinicaltrials.gov: NCT04921384
Steiner TJ, Stovner LJ, Vos T. et al. J Headache Pain 2018; 19: 17.
Leonardi M, Steiner TJ, Scher AT, Lipton RB. J Headache Pain. 2005; 6(6): 429– 440.
Takeshima, T, et al. J Headache Pain 2019; 20, 111
Guidelines for the diagnosis and treatment of migraine in China (2022 edition). Chinese Journal of Pain Medicine 2022, 28 (12)
Ashina M, et al. Cephalalgia. 2020 Mar;40(3):241-254.
Lipton RB, et al. Neurology. 2020 Mar 31;94(13):e1365-e1377.
CONTACT:
H. Lundbeck A/SOttiliavej 9, 2500 Valby, Denmark+45 3630 1311info@lundbeck.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/h--lundbeck-a-s/r/new-data-from-phase-iii-trial-confirms-efficacy-of-vyepti---eptinezumab--in-asian-population-with-ch,c4166989
The following files are available for download:
https://mb.cision.com/Main/18215/4166989/3515989.pdf
EAN 2025 Press Release SUNRISE_Final
View original content:https://www.prnewswire.co.uk/news-releases/new-data-from-phase-iii-trial-confirms-efficacy-of-vyepti-eptinezumab-in-asian-population-with-chronic-migraine-302487650.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
2 hours ago
- CNET
The Best Foods to Put On Your Plate if You Have a Headache
If taking an aspirin or simply lying down isn't cutting it when you have a headache, you may want to consider what's on your plate for relief. While no food will cure headaches or migraines, certain foods may help -- in addition to hydration, exercise, sleep and stress management. "The most important thing I tell patients is that migraines are highly individualized," says Dr. Nicholas Church, a board-certified member of the American Board of Family Medicine and the American Academy of Family Physicians. "What helps one person may not help another, and what's a trigger for one might be therapeutic for someone else." Curious about which foods may help with headache and migraine symptoms? This is what experts have to say. 1. Omega-3-rich foods "I recommend omega-3-rich fish, such as salmon, mackerel and sardines," says Church. "These fish are high in anti-inflammatory fats (EPA and DHA), which can reduce inflammation throughout the body, including in the vascular system and brain." Citing a 2021 randomized controlled trial, Church explains that because migraines are believed to involve inflammatory and vascular changes in the body, omega-3 fatty acids may help reduce their frequency or intensity when eaten regularly. "The study's findings also align with earlier data showing that omega-3s help regulate prostaglandins, which play a role in headache inflammation," says Church. Prostaglandins are hormone-like substances that impact bodily functions like inflammation, pain and menstrual cramps. Fatty fish also contain vitamin D, coenzyme Q10 and B vitamins like riboflavin, which support healthy brain metabolism. Kiran Campbell, a registered dietitian nutritionist at MyNetDiary, also mentions a 2024 meta-analysis revealing that omega-3 fatty acids can reduce the frequency, duration and severity of migraines. She adds that plant-based sources include chia seeds, walnuts, flaxseed and algae oil. Example foods: salmon, mackerel, sardines, chia seeds, walnuts, flaxseed and algae oil Chia and flax seeds are great sources of omega-3s. mikroman6/Getty Images 2. Magnesium-rich foods Daniel Redwood, the director of Human Nutrition and Functional Medicine at the University of Western States, explains, "Attention to the potential importance of magnesium in migraine grew in prominence with the discovery (Ramadan, 1989) that people with migraines had lower levels of this mineral in their red blood cells, serum and brain tissue." Dr. Paul Daidone, medical director at True Self Recovery, seconds this, stating that food rich in magnesium -- like pumpkin seeds, spinach and avocado -- may reduce the severity and occurrence of migraines. He cites a 2022 study examining the potential connection between magnesium deficiency and migraine, which describes how magnesium deficiency is implicated in migraine attacks due to processes like cortical spreading depression, oxidative stress, neurotransmitter imbalance and electrolyte imbalance. "Although clinical evidence of the acute dietary magnesium deficiency as a direct migraine trigger remains limited, scientists are investigating the involvement of intra- and extracellular magnesium levels in migraine pathogenesis," Daidone explains. Dr. Schonze Del Pozo, a board-certified internal medicine physician and medical director at East Sacramento Concierge, states that many of the patients she sees for headaches and migraines are deficient in magnesium. She also cites a 2012 study in the Journal of Neural Transmission entitled "Why all migraine patients should be treated with magnesium." As a result, she recommends a healthy diet of magnesium-rich dark leafy greens like spinach, kale, broccoli and Swiss chard. Example foods: pumpkin seeds, spinach and avocado, kale, broccoli and Swiss chard 3. Ginger "Many swear by ginger as a way to help with migraines," states Dr. Maria Knöbel, a general practitioner and medical director of Medical Cert UK. "Studies have proven that ginger reduces nausea and can decrease the inflammation that leads to migraine pain. Ginger has helped patients during my practice, whether they take it as ginger tea or in supplement form." She references a 2014 study that found ginger powder to be as effective as the medication sumatriptan in treating acute migraine attacks, but with fewer side effects. Ginger tea may be especially beneficial because, Knöbel states, "It's important to drink enough water, as well as eat ginger. Drinking enough water might stop your migraine from getting any worse." Church also recommends ginger because it contains natural anti-inflammatory compounds like gingerol. "I've had patients find relief from migraines or migraine-related nausea using ginger tea, powder or chews," he explains. A 2019 study also found that 400mg of ginger extract, in addition to 100mg of the non-steroidal anti-inflammatory drug ketoprofen, may help treat migraine attacks. Ginger tea combines the benefits of ginger with the hydration of water.4. Nuts and seeds "Another group of foods I recommend are nuts and seeds, including almonds, pumpkin seeds, sunflower seeds and walnuts," Church states. "Like leafy greens, these are rich in magnesium, and some also provide vitamin E, which has been shown to help with menstrual migraines and migraines with aura." A 2015 study reflected this. Example foods: almonds, pumpkin seeds, sunflower seeds and walnuts 5. Cinnamon "Cinnamon contains a high amount of antioxidants that may also reduce headache frequency," Campbell explains. "Stir it into your morning oatmeal or tea, or bake it into muffins and breads." She cites a randomized, double-masked, placebo-controlled 2020 trial, stating, "Studies suggest that cinnamon supplementation may lower inflammation, cutting down on migraine frequency, severity and duration." The antioxidants in cinnamon may help treat headaches and migraines. FreshSplash/Getty Images 6. Foods rich in vitamin B2 "A well-known [1998] randomized controlled trial found that 400 mg of riboflavin daily significantly reduced migraine frequency and severity over a three-month period," Church says. Though this high dose usually comes from supplementation, riboflavin-rich foods support the same metabolic processes in migraine prevention. These foods can include eggs, dairy and lean meats. "Riboflavin is essential for mitochondrial energy production, and many researchers believe that migraines stem in part from dysfunction in energy metabolism within brain cells," Church adds. Redwood adds, "There exists a small but promising body of research on the effectiveness of some nutritional supplements for migraines, especially riboflavin (vitamin B2), coenzyme Q10 and magnesium. The first research-based indicator of riboflavin's potential as a migraine treatment appeared in a small 1946 article by a medical physician, published in the Canadian Medical Association Journal, which reported dramatic effectiveness from what would now be considered low-dose B2 supplements." A 2022 systematic review and meta-analysis found that supplementation of 400mg/day of vitamin B2 for three months affected the duration, frequency and pain score of migraine attacks. Example foods: Eggs, dairy and lean meats 7. Turmeric Curcumin is the active compound in turmeric and, according to Campbell, is "high in antioxidant power and shines especially when paired with omega-3s." To add it to your diet, consider sprinkling it into smoothies, curries or teas. Campbell references a randomized, double-masked, placebo-controlled 2021 trial that concluded, "Present findings revealed that n-3 fatty acids and curcumin co-supplementation can be suggested as a promising new approach in migraine headache management." However, more studies are needed. When combined with omega-3s, turmeric may help with migraine headache management. Rawlstock/Getty Images 8. Whole grains Church mentions that whole grains like quinoa, brown rice and oats may also be beneficial since they "provide a steady release of glucose, preventing blood sugar crashes that can trigger headaches, and are good sources of fiber, B vitamins and trace minerals." He cites a 2023 cross-sectional study of 12,710 participants with all data collected from a 1999-2004 National Health and Nutrition Examination Survey. It found that for every 10 grams of fiber added to the diet, there was an 11% reduction in the odds of having severe headaches or migraines. "By providing magnesium, iron, and B vitamins, whole grains support brain health, oxygen delivery and a stable glucose supply, which are all relevant to migraine prevention," concludes Church. A 2023 comprehensive review also found that curcumin is a promising candidate for preventing and controlling migraines due to its anti‑inflammatory, antioxidative, anti-protein aggregate and analgesic effects. However, additional studies are needed. Example foods: quinoa, brown rice and oats 9. Water-rich foods Dr. Kimberly Idoko, a developmental neurobiologist and board-certified neurologist, reveals that dehydration can also trigger headaches, which is why staying hydrated can significantly improve migraine treatments. "Water-rich foods like cucumber, watermelon and citrus fruits also help you stay hydrated," adds Church. To prevent dehydration-caused headaches or migraines, enjoy more water-rich foods like watermelon. Anucha Muphasa/500px/Getty Images Foods that may trigger headaches or migraines Chocolate, cheese and alcohol: "In one [2007] study of over 500 migraine sufferers, 44% reported at least one food as a trigger. Among the most common triggers were chocolate, cheese and alcohol, " reveals Dr. Adam Lowenstein, a board-certified plastic surgeon who runs the Migraine Surgery Specialty Center. Gluten: "Gluten can be a highly inflammatory food substance, especially among those who are prone to sensitivities or gluten allergy," explains Trista Best, a registered dietitian at The Candida Diet, environmental health specialist and adjunct nutrition professor. "This inflammation causes a host of health conditions, including migraines." When it comes to caffeine, moderation is "The most fascinating study I've seen on the role of nutrition in the treatment of headaches (Hering-Hanit and Gadoth, 2003) was published in Cephalalgia, the premier headache journal. Over a 5-year period, doctors at a neurology clinic in Israel treated 36 children and adolescents (average age 9) with severe daily or near-daily headaches who drank an average of 11 quarts of cola drinks per week," says Redwood. "At the end of a gradual withdrawal period (because too speedy a withdrawal can trigger even worse headaches), 33 of these 36 young people were headache-free, a truly stunning result. Nearly all cola drinks contain substantial amounts of caffeine (Chou and Bell, 2007)." Note: 11 quarts of cola per week is extreme, and the average person doesn't consume this much caffeine. Moderate caffeine intake is still OK, according to Amelia Ti, a registered dietitian and diabetes educator in New York City who is also part of CNET's medical review board. However, when it comes to caffeine, Church notes, "Caffeine, used strategically, can enhance the absorption of pain relievers and constrict dilated blood vessels in the brain, which may ease migraine pain. This is why many over-the-counter headache medications include it. Studies have shown that 40–100 mg of caffeine (the amount in a small cup of coffee or strong tea) can reduce migraine or tension headache pain. But, chronic overuse can lead to rebound headaches, so moderation is key." Added sugars and highly processed foods: "Research has shown that people following a 'Western' diet, which includes substantial amounts of added sugars and other highly processed foods, are at greater than average risk for developing migraines, while the risk is significantly lower than average for those following a healthier diet," states Redwood. download (1) Dr. Joseph Mercola, a board-certified family physician and author of Your Guide to Cellular Health, adds that in addition to incorporating foods rich in specific nutrients like magnesium and B vitamins, you'll want to eliminate triggers like processed foods that contain nitrates, MSG, added sugars or yeast.
Bloomberg
4 hours ago
- Bloomberg
Novo Nordisk Foundation and the Evolution of Quantum Computing: Tech Disruptors
Professor Lene Oddershede Chief Scientific Officer, Planetary Science & Technology at the Novo Nordisk Foundation talks about the applications of quantum computing at the tech disruptors podcast. She discusses the timeline of adoption, roadblocks, standards, benchmarks and the convergence with classic computing.
Bloomberg
6 hours ago
- Bloomberg
Denmark's Economy Runs on Novo. Will the Drugmaker's Troubles Slim It Down?
Denmark's status as one of the few countries in Europe with an expanding economy rests in part on the success of its homegrown hero, Novo Nordisk A/S. Thanks to the pharmaceutical giant's astronomical rise, the country enjoyed growth of 3.5% last year, outpacing most nations in the region. But after a series of stumbles, Novo is struggling to retain its edge in the cutthroat US weight-loss market. That, in turn, is generating concern about whether the company's troubles could lead to mass layoffs or become a drag on the broader Danish economy.
